We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex Boosts Product Portfolio With New xMAP Technology
Read MoreHide Full Article
Luminex Corporation recently delivered the first of its new xMAP INTELLIFLEX Systems to several of its Life Science Research Partners. This marks a significant milestone in the company’s strategy with respect to the expansion of its xMAP Technology with new functionality to facilitate new applications.
In sync with phased rollout of the new INTELLIFLEX solution, Luminex will ship additional units to major research institutions and other partners during third-quarter 2020. By the end 2020, the company intends to fully commercialize this next generation of xMAP Technology.
This announcement is likely to strengthen Luminex’s robust product portfolio further.
xMAP INTELLIFLEX at a Glance
This new system is a modern, compact and solid version of the already successful xMAP platform and is fully compatible with the existing xMAP assay menu. The rollout of this system marks the next step in improved features and functionality on the xMAP platform that is regarded as the industry’s gold standard for multiplexing of biological tests.
Significance of xMAP INTELLIFLEX
The xMAP INTELLIFLEX, which was initially intended for research use only, can help Luminex’s partners to develop novel, high-value assays that cannot be done on existing systems in the market. This is extremely crucial for collaborations amid the pandemic in order to counter the same. The introduction of this system is likely to drive a new wave of advancement in research.
The system has a new key feature — the dual-reporter — that will enable customers to double their multiplex capabilities, thereby allowing them to get more data with less sample, while optimizing workflow.
Other Developments
In June, Luminex submitted an Emergency Use Authorization (EUA) request to the FDA for its xMAP SARS-CoV-2 Multi-Antigen IgG assay. The assay has been created to offer additional capacity to detect antibodies in patients who might have been exposed to or infected by SARS-CoV-2. Notably, this COVID-19 antibody test can deliver outstanding results for up to 96 samples in under three hours and has been developed to run on all xMAP platforms.
In April, Luminex announced that it has received EUA from the FDA for its ARIES SARS-CoV-2 Assay that can rapidly detect the virus causing COVID-19. This development is likely to enable hospital professionals to decide the appropriate course of treatment for patients, who might be infected with COVID-19 within about two hours. Notably, the assay runs on the FDA approved ARIES System, which is a sample-to-answer, automated, on-demand molecular diagnostic platform.
Market Prospects
Per a report by Research and Markets, the global multiplexed diagnostics is expected to see a CAGR of 19.3% between 2018 and 2024. Rising prevalence of chronic diseases is one of the primary factors driving the market.
Hence, the latest development has been a well-timed one for Luminex.
Price Performance
Over the past year, shares of this Zacks Rank #1 (Strong Buy) company have gained 62.5% compared with the industry’s growth of 8.8%.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space include Quest Diagnostics Incorporated (DGX - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) . While Quest Diagnostics sports a Zacks Rank #1, West Pharmaceutical and Laboratory Corporation carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
Quest Diagnostics has an estimated long-term earnings growth rate of 7.6%.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
Laboratory Corporation has an estimated long-term earnings growth rate of 6.1%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Luminex Boosts Product Portfolio With New xMAP Technology
Luminex Corporation recently delivered the first of its new xMAP INTELLIFLEX Systems to several of its Life Science Research Partners. This marks a significant milestone in the company’s strategy with respect to the expansion of its xMAP Technology with new functionality to facilitate new applications.
In sync with phased rollout of the new INTELLIFLEX solution, Luminex will ship additional units to major research institutions and other partners during third-quarter 2020. By the end 2020, the company intends to fully commercialize this next generation of xMAP Technology.
This announcement is likely to strengthen Luminex’s robust product portfolio further.
xMAP INTELLIFLEX at a Glance
This new system is a modern, compact and solid version of the already successful xMAP platform and is fully compatible with the existing xMAP assay menu. The rollout of this system marks the next step in improved features and functionality on the xMAP platform that is regarded as the industry’s gold standard for multiplexing of biological tests.
Significance of xMAP INTELLIFLEX
The xMAP INTELLIFLEX, which was initially intended for research use only, can help Luminex’s partners to develop novel, high-value assays that cannot be done on existing systems in the market. This is extremely crucial for collaborations amid the pandemic in order to counter the same. The introduction of this system is likely to drive a new wave of advancement in research.
The system has a new key feature — the dual-reporter — that will enable customers to double their multiplex capabilities, thereby allowing them to get more data with less sample, while optimizing workflow.
Other Developments
In June, Luminex submitted an Emergency Use Authorization (EUA) request to the FDA for its xMAP SARS-CoV-2 Multi-Antigen IgG assay. The assay has been created to offer additional capacity to detect antibodies in patients who might have been exposed to or infected by SARS-CoV-2. Notably, this COVID-19 antibody test can deliver outstanding results for up to 96 samples in under three hours and has been developed to run on all xMAP platforms.
In April, Luminex announced that it has received EUA from the FDA for its ARIES SARS-CoV-2 Assay that can rapidly detect the virus causing COVID-19. This development is likely to enable hospital professionals to decide the appropriate course of treatment for patients, who might be infected with COVID-19 within about two hours. Notably, the assay runs on the FDA approved ARIES System, which is a sample-to-answer, automated, on-demand molecular diagnostic platform.
Market Prospects
Per a report by Research and Markets, the global multiplexed diagnostics is expected to see a CAGR of 19.3% between 2018 and 2024. Rising prevalence of chronic diseases is one of the primary factors driving the market.
Hence, the latest development has been a well-timed one for Luminex.
Price Performance
Over the past year, shares of this Zacks Rank #1 (Strong Buy) company have gained 62.5% compared with the industry’s growth of 8.8%.
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space include Quest Diagnostics Incorporated (DGX - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) . While Quest Diagnostics sports a Zacks Rank #1, West Pharmaceutical and Laboratory Corporation carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Quest Diagnostics has an estimated long-term earnings growth rate of 7.6%.
West Pharmaceutical has a projected long-term earnings growth rate of 9.2%.
Laboratory Corporation has an estimated long-term earnings growth rate of 6.1%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>